Kornimate/medical-research-clean huggingface dataset:
intravenous immune globulin treatment compared to placebo in patients with myasthenia gravis

Conditions: Myasthenia Gravis

Summary: this study is a double-blind, placebo-controlled, randomized clinical trial to determine whether ivig is effective in improving motor scores in patients with myasthenia gravis and worsening weakness.

patients aged 18 years or older with a diagnosis of myasthenia gravis (mg) and worsening weakness were enrolled in the study after providing informed consent. fifty-two patients were recruited to the study, but one withdrew consent prior to starting so that 51 patients were recruited. baseline clinical assessments using the quantitative mg score for disease severity (qmgs) were repeated at 2 and 4 weeks after treatment with ivig or saline infusion. the post-intervention status was assessed at 2 and 4 weeks after treatment. the treatment was randomized and double-masked. electrophysiological and immunological tests were done at baseline and after 2 weeks. baseline characteristics were compared by the student's t test for continuous variables or chi-square test for categorical variables. an analysis of covariance was performed for the primary outcome measure, the change in qmgs.

Eligibility criteria:
inclusion criteria: * age \> or equal to 18 years old with a confirmed diagnosis of myasthenia gravis and worsening weakness exclusion criteria: * age \<18; severe myasthenia gravis requiring intensive care admission; change in immunosuppresive medication in previous 3 months; patients with severe bulbar weakness at risk for aspiration and respiratory failure; patients with other serious underlying medical conditions (renal failure, congestive heart failure); unwilling to provide informed consent.

Keywords: myasthenia gravis immunoglobulin intravenous immunoglobulin treatment
utah study evaluating apneic oxygenation for emergency department intubation

Conditions: Intubation

Summary: this study will determine rates of first pass success without hypoxemia in emergency department intubations with and without the use of apneic oxygenation by nasal cannula.


Eligibility criteria:
inclusion criteria: - patients requiring emergent rapid sequence or delayed sequence endotracheal intubation with administration of a neuromuscular blocker (succinylcholine, rocuronium) exclusion criteria: * known prisoners * patients in cardiac arrest * patients who are intubated without the use of neuromuscular blockade (i.e., cardiac arrest, awake intubation).

Keywords: hypoxemia intubation apneic oxygenation
diabetic cardiovascular complications: multi-omics analysis

Conditions: Diabetes

Summary: the goal of this observational study is to learn about the molecular mechanisms underlying cardiovascular complications in individuals with type 2 diabetes (t2dm) and how they differ from healthy individuals. the study will also identify biomarkers and potential therapeutic targets for better managing diabetes-related heart disease. the main questions it aims to answer are: 1. what molecular changes are associated with cardiovascular complications in t2dm patients compared to healthy individuals? 2. how do genetic, gene expression, and protein profiles differ between t2dm patients with and without cardiovascular complications? researchers will compare the molecular profiles of three groups: healthy controls, individuals with t2dm but no cardiovascular complications, and those with t2dm and cardiovascular complications. participants will: 1. provide blood samples for genomics, transcriptomics, and proteomics analysis 2. undergo standard clinical tests such as blood pressure, echocardiogram, and ankle-brachial index measurements 3. be followed for 12 to 24 months to track the development of cardiovascular events participate in follow-up phone interviews to record major cardiovascular events like heart attacks or strokes


Eligibility criteria:
inclusion criteria: 1. age: patients aged between 20 and 70 years. 2. coronary angiography: patients who have undergone coronary angiography at the second xiangya hospital of central south university for various reasons. 3. informed consent: patients who have signed the informed consent form and are willing to participate in the collection and analysis of multi-omics data. 4. medical history and samples: patients who can provide complete medical history and biological samples. exclusion criteria: 1. severe diseases or malignancy: patients with other severe diseases or malignancies that may affect the study. 2. cognitive or psychiatric disorders: patients with cognitive or psychiatric disorders that would prevent participation or cooperation in the study. 3. pregnancy or lactation: women who are pregnant or breastfeeding. 4. short life expectancy: patients with a life expectancy of less than 6 months. 5. inability to provide consent: patients unable or unwilling to provide informed consent.

Keywords: multi-omics analysis diabetes cardiovascular complications
enhanced clinics for patients diagnosed with ankylosing spondylitis and psoriatic arthritis

Conditions: Spondylitis, Ankylosing; Psoriatic Arthritis

Summary: the 19.5 months project will pilot the introduction of a hospital-based, nurse-led ankylosing spondylitis (as) and psoriatic arthritis (psa) service for patients being initiated on biologic therapy in nhs lothian edinburgh western general hospital. it is anticipated that this new model of care will improve: 1. the time from referral for biologic therapy to initiation of treatment with a biological therapy due to the dedicated nurse to see patients 2. the management and monitoring of as and psa patients post commencement of treatment , in line with the national institute for health and care excellence (nice) guidelines


Eligibility criteria:
inclusion criteria: * clinical diagnosis of as or psa * referral for initiation of biological therapy by patients regular consultant * age 18 years or older * willing and able to give informed consent exclusion criteria: · unable to comply with study procedures

Keywords: nurse-led service enhanced clinics
causes of pneumonia in yangon

Conditions: Melioidosis Pneumonia

Summary: this study will evaluate a new point of care diagnostic test for the diagnosis of melioidosis pneumonia in patients attending outpatient clinics in yangon, myanmar

melioidosis is caused by burkholderia pseudomallei, a gram-negative saprophytic environmental bacterium that is an important emerging tropical infection. there are an estimated 165,000 cases and 89,000 deaths world-wide each year. eighty-four percent of cases are in se asia where mortality is 40%; far exceeding most recognised neglected tropical diseases. pneumonia, secondary to either inhalation of b.pseudomallei or to bacteraemic spread to the lung is the commonest presentation (51%). annually the highest burden (75%) of infection occurs in the rainy season in (75% in thailand). up to 80% patients have at least one recognised risk factor for melioidosis including; diabetes, alcohol-dependence, glucocorticoid therapy, chronic obstructive pulmonary disease (copd), chronic renal disease and cancer. copd and diabetes mellitus are amongst the top ten causes of death in myanmar (2018). patients with hiv have not been shown to have greater risk of b. pseudomallei than immunocompetent patients. melioidosis was discovered in myanmar in 1911 by british pathologist alfred whitmore and his assistant cs krishnaswami. yet since 1949 there have been few published cases. under-reporting is partly due to difficulty in diagnosing melioidosis. clinical and radiological findings are indistinguishable from tuberculosis. laboratory diagnosis is challenging, lack of facilities, expertise and awareness of b.pseudomallei results in missed diagnostic opportunities. culture is the gold-standard diagnostic method but requires appropriate facilities and expertise which are not readily available in many developing countries like myanmar. a rapid diagnostic (rdt) test has been developed for low resource settings that has been evaluated in laos and india. the inbios® active melioidosis detecttm-lateral flow assay (amd-lfa) detects b.pseudomallei 6-deoxyheptan capsular polysaccharide antigen. shaw et al demonstrated sensitivity 85.71% (ci:74.61% to 93.25%) and specificity 93.62% (ci:88.23% to 97.04%), with positive predictive value of 85.71% (ci: 75.98% to 91.92%) compared to culture. we propose to evaluate this test for the diagnosis of melioidosis pneumonia in myanmar.

Eligibility criteria:
inclusion criteria: 1. \>18 years old 2. reported fever or axillary temperature \> 37.5 °c 3. productive cough 4. written informed consent exclusion criteria: 1. inability to provide a sputum specimen

Keywords: pneumonia melioidosis myanmar diagnosis
comparative analysis of bioxtra on xerostomia

Conditions: Radiation-Induced Xerostomia

Summary: the present study compared the efficacy of bioxtra spray and mouth rinse in the relief of radiotherapy-induced xerostomia in patients referred to cancer institute, tehran imam khomeini hospital.

xerostomia or dry mouth is an important complication of radiotherapy for head and neck regions producing serious discomfort for patients with a significant reduction in their quality of life. symptomatic treatments for the disease include maintain oral hygiene and use of artificial saliva substitutes. due to limited studies on efficacy compounds bioxtra, present study compared the effects of spray and mouth rinse bioxtra in symptoms of xerostomia in patients under head and neck cancer radiotherapy .

Eligibility criteria:
inclusion criteria: * complaint of xerostomia after head and neck radiotherapy * patient must have given written informed consent exclusion criteria: * age under 18 years * history of any treatment for cancer in the last 3 months * recurrence of cancer and end stage of it * diabetes mellitus * sjogren syndrome or other medical causes of xerostomia * drug therapy which might induce xerostomia * refusal of cooperation or consent

Keywords: xerostomia radiotherapy of head and neck bioxtra
evaluation of diagnostic hiv ag/ab combo assay

Conditions: Human Immunodeficiency Viruses

Summary: to test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (hiv). results will be compared to an approved hiv antibody test and supplemental testing performed to determine hiv status.

all specimens collected under separate specimen collection protocols or obtained from specimen suppliers will be provided to the clinical sites performing the investigational hiv test. this includes 6252 specimens collected from normal healthy individuals (7b5-02-05z01-01: collection of specimens used in abbott laboratories in vitro diagnostic hiv and hepatitis assays clinical studies)and from specimen suppliers. 588 specimens from hiv-infected pediatric subjects and 448 pregnant females at risk for hiv infection collected under protocol (7b5-02-05z01-02: collection of pediatric and pregnant female specimens used in the abbott laboratories in vitro diagnostic hiv assay)and from specimen suppliers. all specimens were previously collected and frozen, except for a subset of 586 specimens from normal healthy population and 55 specimen from pregnant females at risk for hiv infection which were collected under separate specimen collection protocols and tested as fresh specimens during the study. in addition, 83 specimens that were hiv antigen positive, 1121 specimens that were hiv-1 antibody positive, 201 specimens that were hiv-2 antibody positive, and 1409 specimens from us at risk for hiv infection or from hiv-2 endemic area were all obtained from specimen suppliers, except for 11 pediatric specimens collected under a separate protocol (7b5-02-05z01-02: collection of pediatric and pregnant female specimens used in the abbott laboratories in vitro diagnostic hiv assay).

Eligibility criteria:
normal healthy population: inclusion criteria: * apparently healthy individual at the time of enrollment as affirmed by the subject exclusion criteria: * hiv infection as affirmed by the subject pregnant female population at risk for hiv infection: inclusion criteria: * subject is a pregnant female * subject has risk factor for hiv infection exclusion criteria: * hiv infection as affirmed by the subject hiv-1 positive pregnant female subjects inclusion criteria: * subject is a pregnant female in first, second, or third trimester * subject must have documented hiv infection exclusion criteria: * none hiv-1 positive pediatric subjects inclusion criteria: * subject must be 2 years to 16 years of age * subject must have documented hiv infection (e.g., western blot positive or hiv rna positive/detectable) exclusion criteria: * none
intravitreal ranibizumab or aflibercept after bevacizumab in diabetic macular edema

Conditions: Diabetic Macular Edema; Diabetic Retinopathy

Summary: purpose: to evaluate the efﬁcacy of switching from bevacizumab to ranibizumab (lucentis; genentech, south san francisco, ca) or aflibercept (eylea; regeneron, tarrytown, ny) in eyes with diabetic macular edema (dme) nonresponders to bevacizumab (avastin; genentech, south san francisco, ca). methods: single-center retrospective comparative study of patients with dme unresponsive to intravitreal bevacizumab that were switched to ranibizumab or aflibercept. best-corrected visual acuity and central foveal thickness will be analysed prior to and 3 months after the switch. oct biomarkers will also analyzed. a p value of 0.05 or less will be considered to be statistically significant. hypothesis: patients will improve anatomically and functionally after switch.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus patients * older than 18 years * with center-involved dme, defined as central subfield thickness (cst) of more than 300 µm on spectral-domain oct (sd-oct). * nonresponsive to bevacizumab, deﬁned as having persistent intraretinal and/or subretinal fluid on optical coherence tomography (oct), i.e csf\>300µm after a minimum of 3 monthly injections, 4 months before switch, regardless of visual acuity (va). exclusion criteria: * additional ocular diseases that could significantly affect the visual acuity such as: * significant vitreoretinal interface abnormality on sd-oct that may contribute to macular edema * age-related macular degeneration * retinal vascular occlusion * central corneal opacity * amblyopia * advanced glaucoma * optic neuropathy * history of ocular trauma or surgery other than uncomplicated cataract extraction * cataract surgery within 3 months before or after bevacizumab switch * unable to provide written informed consent.

Keywords: diabetic macular edema bevacizumab ranibizumab aflibercept bcva oct
ultrasound percapsular nerve group block vs fascia iliaca block for hip fracture

Conditions: Hip Fracture; Analgesia; Acute Pain

Summary: spinal anesthesia (sa) is a widely accepted anesthetic technique for hip fracture repair among elderly. positioning for sa can be extremely painful. effective management of pain is important for these patients comfort. fascia iliaca block (fib) and femoral nerve blocks are commonly used for analgesia in hip fracture patients. however, they often provide a modest reduction in pain. the percapsular nerve group block (peng block) has the advantage that it covers the accessory obturator nerve. aim of the study: compare fib with peng prior to positioning hip fracture patients for standardized sa. in a prospective randomized double blind we included 80 patients aged more than 65 years old, for whom pain was felt when raising the affected limb to 15 degrees. patients were assigned to receive either ultrasound guided fascia iliaca block or percapsular nerve group block using 20 ml lidocaine 1.5% in both groups. we compared pain on positioning for spinal anesthesia using verbal rating scale (vrs 0 = no pain , vrs 1 = mild pain, t 2= severe pain) for both groups. we also recorded different times to perfom block.

the purpose of the study was to compare analgesis effect of percapsula nerve group block to fascia iliaca block prior to positioning hip fracture patients for standardized sa. we included 80 patients reporting pain with verbal rating scale at 2 when raising the affected limb to 15 degrees. all patients admitted to induction room, were given standard monitoring and we randomized to receive either: ultrasound fascia iliaca block using linear high frequency ultrasound probe (10-15mhz) placed in a transverse direction over the anterior thigh below the inguinal ligament. a 50 mm needle was advanced until the tips placed underneath the fascia iliaca and 20 ml 1.5% lidocaine was injected or ultrasound percapsula nerve group block a curvilinear using low-frequency ultrasound probe (2-5mhz) that was initially placed in a transverse plane over the anterior inferior iliac spine and then aligned with the pubic ramus by rotating the probe counter clockwise approximately 45 degrees. in this view, the iliopubic eminence , the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed and than a 100 mm needle was advanced to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly and 20 ml 1.5% lidocaine.we compared pain on positioning for spinal anesthesia and also different time to realise both blocks.

Eligibility criteria:
inclusion criteria: * - patients aged ≥ 65 years old and undergoing hip fracture surgical repair under continuous spinal anesthesia (csa). * patients for whom pain was felt when raising the affected limb to 15 degrees (verbal pain scale =2) exclusion criteria: * - asa physical status ≥ 4. * impaired cognition or dementia. * multiple fractures. * contraindication to regional anesthesia. * patient's disapproval.

Keywords: hip fracture nerve block spinal anesthesia analgesia
the risk of falls index for patients with neuromuscular disorders

Conditions: Inclusion Body Myositis; Myotonic Dystrophy; Facioscapulohumeral Muscular Dystrophies; Myasthenia Gravis; The Falls Efficacy Scale International; The Morse Fall Scale

Summary: the combination of short quantitatively assessing muscular function and balance in combination with short clinical scores, can be a new valid approach to evaluate the patient risk of fall and help to create a quick checkup test to prescribe an appropriate assistive device. the primary goal of this project is to provide a short battery of clinical assessments used to determine risk of falling for patients with neuromuscular diseases (nmd) based on correlation between clinical assessments between two groups of nmd patients and scales used to assess risk of falling for patients.


Eligibility criteria:
inclusion criteria: * patients between 18- and 65-year-old * patients with adequate cognitive and communication function to fill out the scales assessing risk of falling * the neuromuscular disease needs to be confirmed by genetic report and/or disease deepening neurophysiological examination. exclusion criteria: - patients which are not able to perform motoric functional assessments without assistive gait device.
the effect of exercise training on balance and functional status in individuals with osteoarthritis'

Conditions: Osteo Arthritis Knee; Balance

Summary: the aim of this study was to evaluate and compare the effects of clinical pilates exercise training and combined exercise training on balance and functional status in individuals with knee osteoarthritis (oa).


Eligibility criteria:
inclusion criteria: * individuals diagnosed with knee osteoarthritis ii-iii level according to the results of radiological evaluation by kellgren and lawrence * individuals aged between 40 and 70 years * individuals who have pain in his/her either of the knees in 3 month period and who have a vas score of 3 or more * individuals who can walk 10 meters independently (with or without ancillary device) exclusion criteria: * individuals with body mass index 35 and above * individuals with a history of surgery or injury involving the lower limb within the last 1 year (knee / hip endoprosthesis, post-fracture surgery, menisectomy, etc.) * individuals who received hyaluronic acid or corticosteroid injections in the last year * people with severe eyesight, hearing disabilities individuals with neurological deficit or disorder * individuals with regular exercise habits in the last 6 months * individuals with inflammatory rheumatic diseases.
oncologic outcomes and toxicities of salvage treatment in patients with locoregionally recurrent breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer. the main questions it aims to answer are: * clinical outcomes after salvage treatment for locoregional recurrence * adverse events and quality of life after salvage treatment for locoregional recurrence * patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events * molecular signature associated with treatment resistance participants will be assessed by multi-dimensional methods during and after radiation therapy: * assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * assessment for the adverse events according to ctcae version 5.0 * assessment for the molecular signature using residual tissue after pathologic diagnosis * assessment for the quality of life using questionnaires (breast-q)


Eligibility criteria:
inclusion criteria: * female patients with age 18 to 100. * previous standard definitive treatment for initial breast cancer * locoregional recurrence without distant metastasis * planned salvage treatment for locoregional recurrence * informed consent of the participant exclusion criteria: - not anticipated for complying the study protocol